<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675452</url>
  </required_header>
  <id_info>
    <org_study_id>20150161</org_study_id>
    <secondary_id>2015-004777-32</secondary_id>
    <nct_id>NCT02675452</nct_id>
  </id_info>
  <brief_title>AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least one dose level of AMG 176 will achieve acceptable safety and tolerability in
      subjects with relapsed or refractory multiple myeloma and subjects with relapsed or
      refractory acute myeloid leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and
      dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory
      multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia The study
      will be conducted in four parts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and significant laboratory abnormalities</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate PK on different cohorts</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated combination (MTC)</measure>
    <time_frame>6 months on treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate investigational product inactivation of MCL-1</measure>
    <time_frame>6 months on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary efficacy according to the International Myeloma Working Group uniform response criteria</measure>
    <time_frame>6 months on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <condition>Relapsed or Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a - dose exploration of the intervention, AMG 176</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1b dose exploration. The intervention is AMG 176</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 2 Combination therapy The intervention is AMG 176</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3 - Dose exploration. The intervention is AMG 176</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 176</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_label>AMG 176 - Part 2</arm_group_label>
    <arm_group_label>AMG 176 - Part 3</arm_group_label>
    <other_name>Study Investigational Product (IP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: -Pathologically documented, multiple myeloma relapsed or refractory
        disease after at least 2 lines of therapy, -Must be willing and able to undergo bone marrow
        biopsy at screening, -Measurable disease per the IMWG response criteria, -Eastern
        Cooperative Oncology Group (ECOG) performance status of â‰¤ 2, -Satisfactory hematological
        function without transfusion or growth factor support, -Subjects should not have received
        platelet transfusions for at least 1 week prior to screening, -Hemoglobin &gt; 8 g/dL,
        -Subjects may receive RBC transfusions or receive supportive care), -Other Inclusion
        Criteria May Apply.

        EXCLUSION CRITERIA: -Previously received an allogeneic stem cell transplant within 6 months
        OR having received immunosuppressive therapy within the last three months OR having signs
        or symptoms of acute or chronic graft-versus-host disease, -Autologous stem cell transplant
        less than 90 days prior to study day 1, -Multiple myeloma with IgM subtype, -POEMS
        syndrome, -Existing plasma cell leukemia, -Waldenstrom's macroglobulinemia, -Amyloidosis,
        -Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days prior to
        starting treatment, -Topical or inhaled corticosteroids are permitted, -Infection requiring
        intravenous anti-infective treatments within 1 week of study enrollment (day 1), -Other
        exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-6613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

